This inhibition also leads to suppression of PI3K/AKT signaling, activation of the tumor suppressor p27 and suppression of CDK2 thus arresting cell cycle and growth in BC cells [75,76,77]; (ii) Trastuzumab causes endocytosis and degradation of HER2 through blocking the activity of tyrosine kinases [78]; (iii) Preclinical and clinical studies revealed that coating HER2 overexpressed tumor cells by trastuzumab summons more immune cells especially natural killer cells to attack tumor by antibody-dependent cellular cytotoxicity (ADCC) mechanism [79,80]. The gene discussed is AKT1; the disease is neoplasm.